Abrams, S., Hudgens, S., Banderas, B., Krishnan, S., Ito, D., & Li-McLeod, J. (2012). PIH65 Psychometric Validation of the Tummy Tuck Questionnaire. Value in Health, 15(4), A203.
Abrams, S., Hudgens, S., Banderas, B., Krishnan, S., Ito, D., & Li-McLeod, J. (2012, Jun 2-6). Psychometric Validation of the Tummy Tuck Questionnaire. Paper presented at the ISPOR 17th Annual International Meeting, Washington, D.C.
Agarwal, S., Anderseck, B., Van Asch, P., Johnson, J., Hudgens, S., Medcalf, R., & Ziemssen, T. (2013). Early Mobility Impairment: Bridging the Communication Gap between People with Multiple Sclerosis and Their Healthcare Providers. Neurology, 80, P03.221.
Bartley, K., Gable, J., & Hudgens, S. (2015). Psychometric evaluation of emotional well-being in advanced basal cell carcinoma. Quality of Life Research, 24(.), 18.
Bates, D., Burks, J., Globe, D., Signori, M., Hudgens, S., Denys, P., . . . Chancellor, M. (2013). Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool. BMC Neurology, 13(1), 78. doi:10.1186/1471-2377-13-78
Bell, M. L., Floden, L., Rabe, B. A., Hudgens, S., Dhillon, H. M., Bray, V. J., & Vardy, J. L. (2019). Analytical approaches and estimands to take account of missing patient-reported data in longitudinal studies. Patient Relat Outcome Meas, 10, 129-140. doi:10.2147/PROM.S178963
Bhatnagar, V., Hudgens, S., Piault-Louis, E., Jones, L., Beaver, J., Lyerly, K., . . . Kluetz, P. (2020). Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019. Oncologist, 25, 1-3.
Bron, M., Clements, K., Taylor, D., Emptage, N., Hudgens, S., & Dabbous, O. (2010). Impact of HbA1c and Sulfonylurea Use on Hypoglycemia in Type 2 Diabetes Mellitus. Diabetes, 59( ), A207-A208.
Bron, M., Clements, K., Taylor, D., Emptage, N., Hudgens, S., & Dabbous, O. (2010). Predictors of Diabetes-Related, Facility, and Total Medical Costs in Type 2 Diabetes Mellitus. Diabetes, 59( ), A641.
Burks, J., Chancellor, M., Bates, D., Denys, P., DeRidder, D., MacDiarmid, S., . . . Ross, A. P. (2013). Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients. International Journal of MS Care, 15(4), 182-192. doi:10.7224/1537-2073.2012-049
Cella, D., Beaumont, J., Hudgens, S., Marteau, F., Fueilly, M., Gabriel, S., . . . Kulke, M. (2017). Relationship between symptoms and HRQoL benefits in patients (pts) with carcinoid syndrome (CS): A post-hoc analysis of telotristat ethyl (TE) TELESTAR trial. Neuroendocrinology, 105(Supp 1), 232.
Cella, D., Beaumont, J., Hudgens, S., Marteau, F., Fueilly, M., Gabriel, S., . . . Kulke, M. (2017, Mar 8-10). Relationship between symptoms and HRQoL benefits in patients (pts) with carcinoid syndrome (CS): A post-hoc analysis of telotristat ethyl (TE) TELESTAR trial. Paper presented at the 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain.
Cella, D., Beaumont, J. L., Hudgens, S., Marteau, F., Feuilly, M., Houchard, A., . . . Kulke, M. H. (2018). Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clinical Therapeutics, 40(12), 2006-2020 e2002. doi:10.1016/j.clinthera.2018.10.008
Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A. (2003). Measuring the side effects of taxane therapy in oncology: The functional assessment of cancer therapy-taxane (FACT-taxane). Cancer, 98(4), 822-831. doi:10.1002/cncr.11578
Chan, E., Jamieson, C., Metin, H., & Hudgens, S. (2018). Missing data in patient-reported outcomes: regulatory, statistical, and operational perspectives. Value in Health, 21, S1-S268.
Clements, K., Bron, M., Taylor, D., Emptage, N., Hudgens, S., & Dabbous, O. (2010). Impact of HbA (1c) and sulfonylurea use on hypoglycaemia in type 2 diabetes mellitus. Diabetologia, 53( ), Springer Publications.
Cortes, J., Hudgens, S., Twelves, C., Perez, E. A., Awada, A., Yelle, L., . . . Velikova, G. (2015). Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment, 154(3), 509-520. doi:10.1007/s10549-015-3633-7
Dellon, E. S., Collins, M. H., Katzka, D. A., Hudgens, S., Lan, L., Williams, J., . . . Hirano, I. (2020). Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2020.03.060
Evans, C., Humphrey, L., Pelletier, C., & Hudgens, S. (2017). Group Concept Mapping to Understand the Patient Perspective and Burden of Psoriasis. SKIN The Journal of Cutaneous Medicine, 1(3.1), s16.
Floden, L., Hudgens, S., Jamieson, C., Popova, V., Drevets, W., Cooper, K., & Singh, J. (2020). 149 Evaluation of Individual Items on the PHQ-9 and SDS in Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray. CNS spectrums, 25(2), 295-295.
Ghofrani, H.-A., Galiè, N., Grimminger, F., Humbert, M., Keogh, A. M., Rubin, L. J., . . . Hudgens, S. (2013). Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH). European Respiratory Journal, 42(Supp 57), P3419.
Griffiths, P., Floden, L., & Hudgens, S. (2017, Oct 18-21). Scoring and interpretation of daily diary data in the presence of non-ignorable missing data. Paper presented at the 24th Annual Conference of the International Society for Quality of Life Research, Philadelphia, PA, USA.
Griffiths, P., Floden, L. L., & Hudgens, S. (2017). Scoring and interpretation of daily diary data in the presence of non-ignorable missing data. Quality of Life Research, 26(1), 70-70.
Hahn, E. A., Cellal, D., Dobrez, D. G., Shiomoto, G., Taylor, S. G., Galvez, A. G., . . . Du, H. (2003). Quality of life assessment for low literacy Latinos: A new multimedia program for self-administration. Journal of Oncology Management, 12(5), 9-12.
Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., . . . IrisInvestigators. (2003). Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon-alpha plus low-dose cytarabine (Ara-C): Results from the IRIS Study. Journal of Clinical Oncology, 21(11), 2138-2146. doi:10.1200/JCO.2003.12.154
Hahn, E. A., Holzner, B., Kemmler, G., Sperner-Unterweger, B., Hudgens, S. A., & Cella, D. (2005). Cross-cultural evaluation of health status using item response theory: FACT-B comparisons between Austrian and U.S. patients with breast cancer. Evaluation and the Health Professions, 28(2), 233-259. doi:10.1177/0163278705275343
Ho, S. Y., Hudgens, S., & Wiet, R. J. (2003). Comparison of postoperative facial nerve outcomes between translabyrinthine and retrosigmoid approaches in matched-pair patients. Laryngoscope, 113(11), 2014-2020. doi:10.1097/00005537-200311000-00030
Hudgens, S. (2015). ClinRO psychometric validation: analytic and research design considerations. Quality of Life Research, 24(.), 7.
Hudgens, S. (2018, May 19-23). What is the potential of tolerability in drug development. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, Baltimore, MD.
Hudgens, S., Breeze, J., & Spalding, J. (2013). Patient- and clinician-reported satisfaction with pharmacological stress agents for single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). Journal of Medical Economics, 16(6), 828-834. doi:10.3111/13696998.2013.795488
Hudgens, S., Briggs, A., Tremblay, G., Forsythe, A., & Lloyd, A. (2014). Comparison of Methods to Estimate Health State Utilities in Metastatic Breast Cancer (MBC). Value in Health, 17(7), A557. doi:10.1016/j.jval.2014.08.1835
Hudgens, S., Briggs, A., Velikova, G., Forsythe, A., McCutcheon, S., & Kind, P. (2014). Impact of Treatment with Eribulin (Eri) or Capecitabine (Cap) for Metastatic Breast Cancer (Mbc) on Eq–5D Utility Derived from Eortc Qlq–C30. Annals of Oncology, 25(supp 4), iv360.
Hudgens, S., Burbridge, C., Knight-West, O., & Symonds, T. (2017). Optimizing multiple raters in the generation of anchors for evaluating meaningful change. Quality of Life Research, 26, 1-142.
Hudgens, S., Burbridge, C., Knight-West, O., & Symonds, T. (2017, October). Optimizing multiple raters in the generation of anchors for evaluating meaningful change. Paper presented at the 24th Annual Conference of the International Society for Quality of Life Research, Philadelphia, Pennsylvania, USA.
Hudgens, S., Copher, R., Floden, L., & Meier, G. (2018). Understanding quality of life in hepatocellular carcinoma patients. Journal of Clinical Oncology, 36(15_suppl), 4093-4093. doi:10.1200/JCO.2018.36.15_suppl.4093
Hudgens, S., Copher, R., Floden, L., & Meier, G. (2018, June 1-5). Understanding quality of life in hepatocellular carcinoma patients. Paper presented at the 2018 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Hudgens, S., Copher, R., & Meier, G. (2018). Evaluation of The Disease-Specific Items on The Eortc in Hepatocellular Carcinoma Patients Treated with Lenvatinib Or Sorafenib. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, Baltimore, MD.
Hudgens, S., Copher, R., & Meier, G. (2018). Evaluation of The Disease-Specific Items on The Eortc in Hepatocellular Carcinoma Patients Treated with Lenvatinib Or Sorafenib. Value in Health, 21, S37.
Hudgens, S., Copher, R., & Meier, G. (2018). Longitudinal Analysis Of Adjusted EQ-5D Utility Score At Baseline, Progression-Free Survival, And Progression For Lenvatinib Versus Sorafenib. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, Baltimore, MD.
Hudgens, S., Copher, R., & Meier, G. (2018). Longitudinal Analysis Of Adjusted EQ-5D Utility Score At Baseline, Progression-Free Survival, And Progression For Lenvatinib Versus Sorafenib. Value in Health, 21, S35.
Hudgens, S., Dunn, J., Floden, L., & Spencer, G. (2018). Evaluation Of Meaningful Change In Patient-Related Outcomes For Patients With Cutaneous T-Cell Lymphoma. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, Baltimore, MD.
Hudgens, S., Dunn, J., Floden, L., & Spencer, G. (2018). Evaluation Of Meaningful Change In Patient-Related Outcomes For Patients With Cutaneous T-Cell Lymphoma. Value in Health, 21, S38.
Hudgens, S., Dunn, J., Floden, L., & Spencer, G. (2018). Relationship Between Health State And Patient Reported Outcome In Cutaneous T-Cell Lymphoma: An Exploratory Analysis. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, Baltimore, MD.
Hudgens, S., Dunn, J., Floden, L., & Spencer, G. (2018). Relationship Between Health State And Patient Reported Outcome In Cutaneous T-Cell Lymphoma: An Exploratory Analysis. Value in Health, 21, S35.
Hudgens, S., Evans, C., Phillips, E., & Hill, M. (2017). Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. Journal of Patient Reported Outcomes, 1(1), 3. doi:10.1186/s41687-017-0006-5
Hudgens, S., Floden, L., Blacowicz, M., Jamieson, C., Popova, V., Fedgchin, M., . . . Singh, J. (2020). 175 Determining Meaningful Change in Depression Symptoms Assessed with PHQ-9 and SDS in Treatment-resistant Depression Trials of Esketamine Nasal Spray. CNS spectrums, 25(2), 311-312.
Hudgens, S., Forsythe, A., Kontoudis, I., D'Adamo, D., Bird, A., & Gelderblom, H. (2017). Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma. Sarcoma, 2017, 2372135. doi:10.1155/2017/2372135
Hudgens, S., Forsythe, A., Lloyd, A., & Lapuerta, P. (2016). Measuring and understanding quality of survival in oncology. ASCO Annual Meeting Proceedings, 34(3(Supp p)), e291.
Hudgens, S., Gable, J., Kulke, M. H., Bergsland, E., Anthony, L. B., Caplin, M. E., . . . Lapuerta, P. (2017). Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. Journal of Clinical Oncology, 35(4_suppl), 583-583. doi:10.1200/JCO.2017.35.4_suppl.583
Hudgens, S., Gale, R. P., Tencer, T., & Khan, Z. (2013). PCN112 - Use Of The Functional Assessment Of Cancer Therapy-Anemia (Fact-An) Instrument In Persons With Mpn-Associated Myelofibrosis And Anemia. Value in Health, 16(3), A148. doi:https://doi.org/10.1016/j.jval.2013.03.726
Hudgens, S., Globe, D., Norquist, J., & Reeve, B. (2012, Jun 2-6). Utilization of Rasch Measurement Models for Assessing Validity: A Mixed Methods Approach. Paper presented at the ISPOR 17th Annual International Meeting, Washington, D.C.
Hudgens, S., Globe, D., Norquist, J., & Reeve, B. (2012). Utilization of Rasch Measurement Models for Assessing Validity: A Mixed Methods Approach. On Demand Webcast, March 12, 2012.
Hudgens, S., Harper, J. C., Daniels, S. R., Banderas, B., Varon, S., & Alexis, A. F. (2015). Validation of a New Patient-Reported Outcome Measure for Facial Acne: The Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol, 14(6), 552-559.
Hudgens, S., & Marquis, P. (2012). Rasch measurement: a mixed methods approach for assessing content validity. ISOQOL International Meeting proceedings. Budapest, Hungary, October 24-27. Quality of Life Research, 21( ), 40.
Hudgens, S., McGraw, J., & Craun, M. (1991). Two cases of tension pneumopericardium following blunt chest injury. Journal of Trauma, 31(10), 1408-1410. doi:10.1097/00005373-199110000-00018
Hudgens, S., & Misra, S. (2012). Perspectives on Mixed Methods to Assess Content Validity of a PRO Measure. ISOQOL International Meeting proceedings. Budapest, Hungary, October 24-27. Quality of Life Research, 21( ).
Hudgens, S., Misurski, D., & Meier, G. (2017). Detrimental Impact of Toxicity on Quality of Life In Hepatocellular Carcinoma Patients Treated with Lenvatinibor Sorafenib. Value in Health, 20(9), A411-A412.
Hudgens, S., Misurski, D., & Meier, G. (2017, Nov 4-8). Detrimental Impact of Toxicity on Quality of Life In Hepatocellular Carcinoma Patients Treated with Lenvatinibor Sorafenib. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress, Glasgow, Scotland, UK.
Hudgens, S., Misurski, D., & Meier, G. (2017). Time To Clinically Meaningful Worsening In Hepatocellular Carcinoma Patients Treated With Lenvatinib or Sorafenib. Value in Health, 20(9), A416.
Hudgens, S., Misurski, D., & Meier, G. (2017, Nov 4-8). Time To Clinically Meaningful Worsening In Hepatocellular Carcinoma Patients Treated With Lenvatinib or Sorafenib. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress, Glasgow, Scotland, UK.
Hudgens, S., Pelletier, C., Forsythe, A., & Taylor, M. (2015). Capturing Quality of Life (Qol) Data in Rare Indications: Case Study in Radioiodine-Refractory Thyroid Cancer (Rr-Dtc). Value in Health, 18(7), A726.
Hudgens, S., Pelletier, C., Newton, L., Howerter, A., Gaines, J., Keith, S., . . . Evans, C. (2019). PSS23 Disease Burden in Patients with Mild Psoriasis: Group Concept Mapping. Value in Health, 22, S890.
Hudgens, S., Porcu, P., Quaglino, P., Huen, A., Floden, L., Leoni, M., & Duvic, M. (2018). Evaluation of symptom and side effect bother in cutaneous T-cell lymphoma patients treated with mogamulizumab or vorinostat. Blood, 132(Supplement 1), 3592-3592.
Hudgens, S., Ramage, J., Kulke, M., Bergsland, E., Anthony, L., Caplin, M., . . . Lapuerta, P. (2019). Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. J Patient Rep Outcomes, 3(1), 64. doi:10.1186/s41687-019-0153-y
Hudgens, S., Schuler, R., Stokes, J., Eremenco, S., Hunsche, E., & Leist, T. P. (2019). Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis. Value in Health, 22(4), 453-466. doi:10.1016/j.jval.2018.11.007
Hudgens, S., Spalding, J., & Chaudhari, P. (2016). Validation of a Patient-reported Outcome (PRO) Measure and a Clinician-reported Outcome (CRO) Measure to Assess Satisfaction with Pharmacologic Stress Agents for Single-photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI). Clinical Therapeutics, 38(5), 1141-1150. doi:10.1016/j.clinthera.2016.02.024
Hudgens, S., Taylor-Strokes, G., De Courcy, J., Kontoudis, I., Tremblay, G., Forsythe, A., & Lloyd, A. (2016). Real-World Evidence on Health States Utilities in in Metastatic Breast Cancer Patients: Data from a Retrospective Patient Record Form Study and A Cross-Sectional Patient Survey. ISPOR 21st Annual International Meeting Research. Value in Health, 19(3), A157.
Hudgens, S. A., Cella, D., Caprini, C. A., & Caprini, J. A. (2003). Deep vein thrombosis: validation of a patient-reported leg symptom index. Health and Quality of Life Outcomes, 1, 76. doi:10.1186/1477-7525-1-76
Humphrey, L., Pelletier, C., Hudgens, S., & Evans, C. (2018). Group concept mapping to understand the burden of psoriasis. Journal of the American Academy of Dermatology, 79(3).
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., . . . Duvic, M. (2017). Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the Phase III MAVORIC Study. Blood, 130(Supp 1), 817.
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., . . . Duvic, M. (2017, Dec 9-12). Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the Phase III MAVORIC Study. Paper presented at the 59th Annual Meeting of the American Society of Hematology, Atlanta, GA, USA.
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., . . . Investigators, M. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology, 19(9), 1192-1204. doi:10.1016/S1470-2045(18)30379-6
Kimball, A., Sundaram, M., & Hudgens, S. (2013). Evaluation of factors associated with cumulative life course impairment using a novel patient reported outcome for patients with psoriasis (P6638). Journal of the American Academy of Dermatology, 68(4(supp 1)), AB200.
Kimball, A. B., Sundaram, M., Shields, A. L., Hudgens, S., Okun, M., Foley, C., & Ganguli, A. (2018). Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. Journal of the American Academy of Dermatology, 79(6), 1141-1143. doi:10.1016/j.jaad.2018.05.015
Lasiter, L., Campbell, A., Basch, E., Hudgens, S., Stewart, M., Wu, J. J., . . . Allen, J. (2020). Use of Patient-Reported Outcomes to Understand & Measure the Patient Experience of Novel Cell and Gene Therapies. Therapeutic Innovation & Regulatory Science. doi:10.1007/s43441-020-00184-6
Li, J., Kang, J., Hunsche, E., & Hudgens, S. (2019). The Bleeding and Pelvic Discomfort Scale-Measuring Patient-Reported Symptoms in Uterine Fibroids. Value in Health, 22(Supp 3), S637-S638.
Li, J., Kang, J. B., Hunsche, E., & Hudgens, S. (2019). Measuring patient-reported outcomes in women with heavy menstrual bleeding associated with uterine fibroids: the bleeding and pelvic discomfort scale. Fertility and Sterility, 112(3), e344.
Li, Y., Morris, S., Cole, J., Dube, S., Smith, J. A. M., Burbridge, C., . . . Wang, W. (2017). Multidimensional daily diary of fatigue-fibromyalgia-17 items (MDF-fibro-17): part 2 psychometric evaluation in fibromyalgia patients. BMC Musculoskeletal Disorders, 18(1), 198. doi:10.1186/s12891-017-1545-x
Mahmoud, D., Hudgens, S., Taylor, F., Pompilus, F., Hwang, S., & Beach, C. (2012). Quality of life and productivity impact of myelodysplastic syndromes (MDS): the patient perspective. Blood, 120(21).
Mahmoud, D., Hudgens, S., Taylor, F., Pompilus, F., Hwang, S., & Beach, C. (2013). P-264 Health-related quality of life and productivity impact of myelodysplastic syndromes (MDS): The patient perspective. Leukemia Research, 37(Supp 1), S142.
McDermott, M. M., Hahn, E. A., Greenland, P., Cella, D., Ockene, J. K., Brogan, D., . . . Hudgens, S. (2002). Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician survey. Journal of General Internal Medicine, 17(12), 895-904. doi:10.1046/j.1525-1497.2002.20307.x
Mody, R., Hudgens, S., Han, C., & Perez, M. C. (2010). W1121 Long-Term Benefits of Dexlansoprazole MR on Quality of Life and Symptom Severity Among Gastroesophageal Reflux Disease (GERD) Patients. Gastroenterology, 138(5), S-656.
Morris, S., Li, Y., Burbridge, C., Symonds, T., & Hudgens, S. (2015). AB0949 Development of the Multidimensional Daily Diary of Fatigue Symptoms-Fibromyalgia-17 Item Instrument (DFS-Fibro-17) in Fibromyalgia Patients. Annals of the Rheumatic Diseases, 74(Suppl 2), 1216. doi:10.1136/annrheumdis-2015-eular.4581
Mutebi, A., M., S., Warholak, T. L., Hudgens, S., & Coons, S. J. (2015). ClinRO psychometric validation: analytic and research design considerations. Quality of Life Research, 24(.), 49.
Mutebi, A., Slack, M., Warholak, T. L., Hudgens, S., & Coons, S. J. (2016). Interpretation of verbal descriptors for response options commonly used in verbal rating scales in patient-reported outcome instruments. Quality of Life Research, 25(12), 3181-3189. doi:10.1007/s11136-016-1333-3
Newton, L., DeLozier, A. M., Griffiths, P. C., Hill, J. N., Hudgens, S., Symonds, T., . . . Silverberg, J. I. (2019). Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. Journal of patient-reported outcomes, 3(1), 42. doi:10.1186/s41687-019-0128-z
Newton, L., Knight-West, O., Eremenco, S., Hudgens, S., Crescioni, M., Symonds, T., . . . Vallow, S. (2018). Comparability of a Provisioned Device Versus Bring Your Own Device for Completion of Patient-Reported Outcome (PRO) Measures by Participants with Chronic Obstructive Pulmonary Disease (COPD): Qualitative Interview Findings. Value in Health, 21, S418-S418.
Nolte, S., Coon, C., Hudgens, S., & Verdam, M. G. E. (2019). Psychometric evaluation of the PROMIS(R) Depression Item Bank: an illustration of classical test theory methods. J Patient Rep Outcomes, 3(1), 46. doi:10.1186/s41687-019-0127-0
O'Brien, M., Hudgens, S., King, J., McNally, R., & Khan, Z. (2012, Jun 2-6). Evaluating Meaningful Change on the Lung Cancer Symptom Scale in Small Cell Lung Cancer: Results From a Phase III Clinical Trial. Paper presented at the ISPOR 17th Annual International Meeting, Washington, D.C.
O'Brien, M., Hudgens, S., King, J., McNally, R., & Khan, Z. (2012). PCN111 Evaluating Meaningful Change on the Lung Cancer Symptom Scale in Small Cell Lung Cancer: Results From a Phase III Clinical Trial. Value in Health, 15(4), A227-A228.
Oza, A., Matulonis, U., Malander, S., Hudgens, S., Sehouli, J., del Campo, J., . . . Lund, B. (2017). 930O Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial. Annals of Oncology, 28(suppl_5), v330.
Oza, A., Matulonis, U., Malander, S., Hudgens, S., Sehouli, J., del Campo, J., . . . Lund, B. (2017, Sep 8-12). 930O Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial. Paper presented at the 42nd European Society for Medical Oncology Congress, Madrid, Spain.
Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., Del Campo, J. M., . . . Berek, J. S. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. The Lancet Oncology, 19(8), 1117-1125. doi:10.1016/S1470-2045(18)30333-4
Patterson, M., Dali, C. I., Symonds, T., Guldberg, C., Hudgens, S., & Mengel, E. (2019, 3-6 September). A Study to Assess the Inter-and Intra-rater Reliability of the 5-domain NPCCSS. Paper presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, Rotterdam, Netherlands.
Patterson, M., Dali, C. I., Symonds, T., Guldberg, C., Hudgens, S., & Mengel, E. (2019). A Study to Assess the Inter-and Intra-rater Reliability of the 5-Domain NPCCSS. Annals of Neurology, 86, S143-S144.
Pavel, M., Cella, D., Beaumont, J., Hudgens, S., Marteau, F., Feuilly, M., . . . Hörsch, D. (2017). 445P Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: Post-hoc analyses from TELESTAR. Annals of Oncology, 28(Supp 5), v148-v149.
Pavel, M., Cella, D., Beaumont, J., Hudgens, S., Marteau, F., Feuilly, M., . . . Hörsch, D. (2017, Sep 8-12). 445P Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: Post-hoc analyses from TELESTAR. Paper presented at the 42nd European Society for Medical Oncology Congress, Madrid, Spain.
Pavel, M. E., Gable, J., Kulke, M. H., Bergsland, E., Anthony, L. B., Caplin, M. E., . . . Hudgens, S. (2017). Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. Oncology Research and Treatment, 40(1 (Supp 3)), 238.
Piault-Louis, E., Petersen, J., Gable, J., & Hudgens, S. (2015). Documenting the impact of alopecia in breast cancer: Assessing the performance of the alopecia patient assessment (APA) questionnaire. ASCO Annual Meeting Proceedings, 33(28(supp)), 84.
Pompilus, F., Burgess, S., Hudgens, S., Banderas, B., & Daniels, S. (2015). Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: facial line satisfaction questionnaire. Journal of Cosmetic Dermatology, 14(4), 274-285. doi:10.1111/jocd.12166
Porcu, P., Hudgens, S., Quaglino, P., Cowan, R., Floden, L., Leoni, M., . . . Duvic, M. (2018, Jun 1-5). Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Paper presented at the 2018 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Porcu, P., Hudgens, S., Quaglino, P., Cowan, R., Floden, L., Leoni, M., . . . Duvic, M. (2018). Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Journal of Clinical Oncology, 36(15_suppl), 7577-7577. doi:10.1200/JCO.2018.36.15_suppl.7577
Ramdharry, G., Morrow, J., Hudgens, S., Skorupinska, I., Gwathmey, K., Currence, M., . . . Machado, P. M. (2019). Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. Muscle and Nerve, 60(2), 161-168. doi:10.1002/mus.26521
Rosa, K., Delgado-Herrera, L., Zeiher, B., Banderas, B., Arbuckle, R., Spears, G., & Hudgens, S. (2016). Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event Log. Quality of Life Research, 25(12), 3197-3208. doi:10.1007/s11136-016-1335-1
Rosengart, T. K., Finnin, E. B., Hudgens, S. A., Hahn, E. A., Curran, R. D., Votapka, T. V., . . . McDonough, T. J. (2003). Predictors of saphenous vein graft patency: A risk assessment based on a longitudinal analysis of 100 consecutive post-coronary bypass angiographic studies. Journal of the American College of Cardiology, 41(6S2), 499-499.
Saab, S., Mehta, D., Hudgens, S., Grunow, N., Bao, Y., & Pinsky, B. (2017). Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir+ dasabuvir regimen on patient’s health related quality of life: analysis of Phase 3a and phase 3b clinical trials. Journal of Hepatology, 66(1), S736.
Saab, S., Mehta, D., Hudgens, S., Grunow, N., Bao, Y., & Pinsky, B. (2017, Apr 19-23). Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir+ dasabuvir regimen on patient’s health related quality of life: analysis of Phase 3a and phase 3b clinical trials. Paper presented at the International Liver Congress 2017 - 52nd Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands.
Saab, S., Mehta, D., Hudgens, S., Grunow, N., Bao, Y., & Pinsky, B. (2018). Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C. Liver International, 38(8), 1377-1394. doi:10.1111/liv.13690
Saad, F., Cella, D., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S., . . . Small, E. J. (2018). Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncology, 19(10), 1404-1416. doi:10.1016/S1470-2045(18)30456-X
Saps, M., Hudgens, S., Mody, R., Lasch, K., Harikrishnan, V., & Baum, C. (2013). Seasonal patterns of abdominal pain consultations among adults and children. Journal of Pediatric Gastroenterology and Nutrition, 56(3), 290-296. doi:10.1097/MPG.0b013e3182769796
Saps, M., Hudgens, S., Mody, R., Lasch, K., Harikrishnan, V., & Baum, C. (2013). Seasonal patterns of abdominal pain consultations among adults and children. Journal of Pediatric Gastroenterology and Nutrition, 56(3), 290-296.
Saps, M., Hudgens, S. A., Mody, R., Lasch, K., Harikrishnan, V., & Baum, C. (2010). M1336 Comparison of Seasonal Patterns of Abdominal Pain Consultations (APC) Among Adults and Children. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting. Gastroenterology, 138(5), S-382-S-383.
Sheppard, J., Joshi, A., Betts, K. A., Hudgens, S., Tari, S., Chen, N., . . . Dick, A. D. (2017). Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmology, 135(6), 511-518. doi:10.1001/jamaophthalmol.2017.0603
Shields, A. L., Hudgens, S., Spalding, J., Kitt, T., Ojo, O., Kristy, R. M., . . . Houle, C. R. (2018). Patient and Clinician Satisfaction with Pharmacological Stress Agents (PSAS) Used in Single Photon Emission Computerized Tomography Myocardial Perfusion Imaging (SPECT-MPI). Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, Baltimore, MD.
Shields, A. L., Hudgens, S., Spalding, J., Kitt, T., Ojo, O., Kristy, R. M., . . . Houle, C. R. (2018). Patient and Clinician Satisfaction with Pharmacological Stress Agents (PSAS) Used in Single Photon Emission Computerized Tomography Myocardial Perfusion Imaging (SPECT-MPI). Value in Health, 21, S172.
Socinski, M. A., Schell, M. J., Bakri, K., Peterman, A., Lee, J. H., Unger, P., . . . Kies, M. S. (2002). Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer, 95(6), 1265-1273. doi:10.1002/cncr.10835
Song, K. W., Dimopoulos, M. A., Weisel, K. C., Moreau, P., Lacy, M., Delforge, M., . . . San Miguel, J. (2013). Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM+ LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. Journal of Clinical Oncology, 31(15).
Spalding, J., Hudgens, S., Litcher-Kelly, L., Shields, A., Kitt, T., Ojo, O., . . . Morrissey, L. (2016). Psychometric Analyses of Clinical Outcome Assessment (COA) Questionnaires Designed to Evaluate Satisfaction with Pharmacological Stress Agents (PSAS) Used in Echocardiography. Value in Health, 19(7), A358.
Spalding, J., Hudgens, S., Litcher-Kelly, L., Shields, A., Kitt, T., Ojo, O., . . . Morrissey, L. (2016, Oct 29 - Nov 2). Psychometric Analyses of Clinical Outcome Assessment (COA) Questionnaires Designed to Evaluate Satisfaction with Pharmacological Stress Agents (PSAS) Used in Echocardiography. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress, Vienna, Austria.
Sun, S. X., Bron, M., Spanheimer, R., Hudgens, S., Ramalakar, R., & Hariri, A. (2010). Metformin use among patients with type 2 diabetes and renal impairment. Diabetalogia, 53, Springer Publications.
Teal, S., Brohan, E., Hettema, Y., Humphrey, L., Willgoss, T., Hudgens, S., . . . Cappelleri, J. (2013). Item Refinement and Psychometric Testing of a Novel Survey for Evaluating Patient Perception and Preference for Haemophilia a Treatment. Value in Health, 16(7), A597.
Teal, S., Brohan, E., Hettema, Y., Humphrey, L., Willgoss, T., Hudgens, S., . . . Cappelleri, J. C. (2014). Development and psychometric evaluation of a novel tool for assessing patient perception and preference for haemophilia treatment (HaemoPREF). Haemophilia, 20(5), 666-673. doi:10.1111/hae.12432
Tefferi, A., Hudgens, S., Mesa, R., Gale, R. P., Verstovsek, S., Passamonti, F., . . . Khan, Z. M. (2014). Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clinical Therapeutics, 36(4), 560-566. doi:10.1016/j.clinthera.2014.02.016
Theodore-Oklota, C., Humphrey, L., Wiesner, C., Schnetzler, G., Hudgens, S., & Campbell, A. (2016). Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. Patient Prefer Adherence, 10, 1767-1776. doi:10.2147/PPA.S108489
Velikova, G., Hudgens, S., Forsythe, A., McCutcheon, S., & Cortes, J. (2014). Health-related quality of life (HRQOL) and disease symptoms in patients (PTS) with locally advanced or metastatic breast cancer (MBC) treated with eribulin (ERI) or capecitabine (CAP) in a post anthracycline and taxane setting. Annals of Oncology, 25(supp 4), iv129.
Vogel, A., Qin, S., Kudo, M., Hudgens, S., Yamashita, T., Yoon, J., . . . Breder, V. (2017). Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Hepatology, 66(Supp1), 734a.
Vogel, A., Qin, S., Kudo, M., Hudgens, S., Yamashita, T., Yoon, J., . . . Breder, V. (2017, Oct 20-24). Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Paper presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, D.C.
Vogel, A., Qin, S., Kudo, M., Hudgens, S., Yamashita, T., Yoon, J., . . . Breder, V. (2017). Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Value in Health, 20(9), A454-A455.
Vogel, A., Qin, S., Kudo, M., Hudgens, S., Yamashita, T., Yoon, J., . . . Breder, V. (2017, Nov 4-8). Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Paper presented at the ISPOR 20th Annual European Congress, Glasgow, Scotland, UK.
Vogel, A., Qin, S., Kudo, M., Hudgens, S., Yamashita, T., Yoon, J.-H., . . . Sung, M. (2017). Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Annals of Oncology, 28(Supp 5), v210.
Vogel, A., Qin, S., Kudo, M., Hudgens, S., Yamashita, T., Yoon, J.-H., . . . Sung, M. (2017, Sep 8-12). Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Paper presented at the 42nd European Society for Medical Oncology Congress, Madrid, Spain.